company background image

Celltrion Healthcare KOSDAQ:A091990 Stock Report

Last Price


Market Cap







30 Nov, 2023


Company Financials +

Celltrion Healthcare Co., Ltd.

KOSDAQ:A091990 Stock Report

Mkt Cap: ₩11.2t

A091990 Stock Overview

Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world.

A091990 fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance2/6
Financial Health5/6

Celltrion Healthcare Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion Healthcare
Historical stock prices
Current Share Price₩74,500.00
52 Week High₩81,400.00
52 Week Low₩53,600.00
1 Month Change12.03%
3 Month Change15.15%
1 Year Change17.93%
3 Year Change-40.68%
5 Year Change13.60%
Change since IPO75.07%

Recent News & Updates

Recent updates

Shareholder Returns

A091990KR HealthcareKR Market

Return vs Industry: A091990 exceeded the KR Healthcare industry which returned 10.3% over the past year.

Return vs Market: A091990 exceeded the KR Market which returned 3.5% over the past year.

Price Volatility

Is A091990's price volatile compared to industry and market?
A091990 volatility
A091990 Average Weekly Movement4.4%
Healthcare Industry Average Movement4.9%
Market Average Movement5.8%
10% most volatile stocks in KR Market12.2%
10% least volatile stocks in KR Market2.9%

Stable Share Price: A091990 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A091990's weekly volatility (4%) has been stable over the past year.

About the Company

1999149Hyoung Ki Kim

Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd.

Celltrion Healthcare Co., Ltd. Fundamentals Summary

How do Celltrion Healthcare's earnings and revenue compare to its market cap?
A091990 fundamental statistics
Market Cap₩11.19t
Earnings (TTM)₩43.13b
Revenue (TTM)₩2.22t


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A091990 income statement (TTM)
Cost of Revenue₩1.59t
Gross Profit₩624.94b
Other Expenses₩581.81b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date


Earnings per share (EPS)274.94
Gross Margin28.18%
Net Profit Margin1.94%
Debt/Equity Ratio17.1%

How did A091990 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio